Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia

American Journal of the Medical Sciences

Volumn 337, Issue 1, 2009, Pages 28-36

  Annane, Djillali ^a   Decaux, Guy ^b   Smith, Neila ^c  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b ERASME HOSPITAL   (Belgium)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Arginine vasopressin receptor antagonist; Conivaptan; Euvolemia; Hypervolemia; Hyponatremia

Indexed keywords

ARGIPRESSIN; CONIVAPTAN; PLACEBO; SODIUM ION; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; BENZAZEPINE DERIVATIVE; SODIUM; VASOPRESSIN RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HEART FAILURE; HUMAN; HYPERVOLEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; BLOOD; DRUG ANTAGONISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; BENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; SODIUM;

EID: 62249203665     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31817b8148     Document Type: Article

References (42)

1. Kugler JP, Hustead T. Hyponatremia and hypernatremia in the elderly. Am Fam Physician 2000;61:3623-3630
2. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342: 1581-1589
3. Fall PJ. Hyponatremia and hypernatremia. A systematic approach to causes and their correction. Postgrad Med 2000;107:75-82.
4. Milionis HJ, Liamis GL, Elisaf MS. The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ 2002;166:1056-1062 (Pubitemid 34304651)
5. Kapoor M, Chan GZ. Fluid and electrolyte abnormalities. Crit Care Clin 2001;17:503-529
6. Gross P, Reimann D, Henschkowski J, et al. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2001;12:S10-S14. (Pubitemid 32119048)
7. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119:71.e1-e8. (Pubitemid 43117475)
8. Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994;4:1522-1530
9. Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med 1987;317:1190-1195
10. Soupart A, Decaux G. Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol 1996;46:149-169 (Pubitemid 26306525)
11. Thurman JM, Halterman RK, Berl T. Therapy of dysnatremia disorders. In: Brady HR, Wilcox CS, editors. Therapy in nephrology and hypertension, London, England: WB Saunders; 2003. p. 335-348
12. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002;29:1-9.
13. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001;138:18-21. (Pubitemid 32589198)
14. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001;110:582-584
15. Saito T, Ishikawa S, Abe K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997;82:1054-1057 (Pubitemid 27166641)
16. Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-191 (Pubitemid 36042159)
17. Soupart A, Gross P, Legros J-J, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006;1:1154-1160
18. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112 (Pubitemid 44749318)
19. Inoue T, Ohnishi A, Matsuo A, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998;63:561-570 (Pubitemid 28277277)
20. Gerbes AL, Gülberg V, Ginès P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized doubleblind multicenter trial. Gastroenterology 2003;124:933-939 (Pubitemid 36389796)
21. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997;282:301-308
22. Risvanis J, Naitoh M, Johnston CI, et al. In vivo and in vitro characterization of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat. Eur J Pharmacol 1999;381:23-30.
23. 2 receptor antagonist, in dogs. Eur J Pharmacol 1997;321:225-230
24. 2 receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol 2003;38:755-761
25. Wada K, Tahara A, Arai Y, et al. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. Eur J Pharmacol 2002;450:169-177 (Pubitemid 35232243)
26. 2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 1999;55:633-637
27. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104: 2417-2423
28. 2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91: 2145-2152
29. Zeltser D, Rosansky S, van Rensburg H, et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007;27:447-457 (Pubitemid 47482001)
30. Goldberg M. Hyponatremia. Med Clin North Am 1981;65:251-269
31. Shoker AS. Application of the clearance concept to hyponatremic and hypernatremic disorders: a phenomenological analysis. Clin Chem 1994;40:1220-1227
32. Chen S, Jalandhara N, Batlle D. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat Clin Pract Nephrol 2007;3:82-95. (Pubitemid 46161000)
33. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981;2:93-113.
34. Dunnett CW. New tables for multiple comparisons with a control. Biometrics 1964;20:482-491
35. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096-1121
36. Creager MA, Faxon DP, Cutler SS, et al. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986;7:758-765 (Pubitemid 16107118)
37. Goldsmith SR. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists? Am J Med 2006; 119:S93-S96.
38. Tomura Y, Tahara A, Tsukada J, et al. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin Exp Pharmacol Physiol 1999;26:399-403. (Pubitemid 29306955)
39. 2 receptor antagonist, on vasopressininduced cardiac and haemodynamic changes in anaesthetised dogs. Pharmacol Res 2002;46:375-381
40. Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 2003;35:1495-1499
41. Decaux G, Soupart A. Treatment of symptomatic hyponatremia. Am J Med Sci 2003;326:25-30.
42. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120:S1-S21.